We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,225

Ford Succeeds In Invalidating Some, But Not All, Claims Of Two Paice’s Patents Related To Hybrid Vehicles
  • Hunton Andrews Kurth LLP
  • USA
  • February 1 2018

Patent owner Paice appealed from PTAB’s final written decisions in six inter partes reviews (“IPR”) holding certain challenged claims of its two


Statement of Agreement or Disagreement with Attorney Argument Alone Does Not Provide Substantial Evidence To Support PTAB Findings
  • Marshall Gerstein & Borun LLP
  • USA
  • July 26 2017

In Google Inc. v. Intellectual Ventures II LLC, Appeal 2016-1543, 2016-1545 (Fed. Cir. July 10, 2017), the Federal Circuit affirmed the PTAB’s final


PTAB Cannot Treat Pre-AIA Means-Plus-Function Limitations As Purely Functional Under the Broadest Reasonable Interpretation Standard
  • Hunton Andrews Kurth LLP
  • USA
  • July 7 2017

Pre-AIA 112 6 (means-plus-function) claim construction analysis requires that the Board not only identify the particular claimed function, but also


Asetek Danmark AS v. CMI USA Inc., Nos. 2016-1026, 2016-1183 (Fed. Cir. Apr. 3, 2017)
  • Winston & Strawn LLP
  • USA
  • June 22 2017

A non-party must be sufficiently “legally identified” with the an enjoined party to be enjoined for conduct other than abetting a new violation


Rembrandt Wireless v. Samsung Electronics, No. 2016-1729 (Fed. Cir. Apr. 17, 2017)
  • Winston & Strawn LLP
  • USA
  • June 22 2017

Licensee's failure to mark may limit a patent owner's recovery of pre-suit damages even for a disclaimed patent claim The patent owner sued alleging


Federal Circuit Reverses Finding Of No Violation of Section 337 And Remands In One-E-Way Appeal (2016-2105)
  • Oblon
  • USA
  • June 21 2017

On June 12, 2017, the U.S. Court of Appeals for the Federal Circuit issued its precedential opinion in One-E-Way, Inc. v. ITC (2016-2105). This was


Sandoz Inc. v. Amgen Inc.
  • Merchant & Gould
  • USA
  • June 16 2017

In a unanimous decision in Sandoz Inc. v. Amgen Inc., the U.S. Supreme Court held that injunctive relief was not available under federal law to


SCOTUS Ruling Gives a Boost to Biosimilars; FDA Continues to Advance Products Through AdComs
  • Mintz Levin
  • USA
  • June 14 2017

On a sweltering hot D.C. morning, those of us anxiously awaiting the Supreme Court’s opinion in its first case involving biosimilar biological


Supreme Court Issues Highly Anticipated Decision Interpreting the Biologics Price Competition and Innovation Act
  • Kramer Levin Naftalis & Frankel LLP
  • USA
  • June 12 2017

On June 12, the Supreme Court decided Sandoz Inc. v. Amgen Inc., the first case under the Biologics Price Competition and Innovation Act of 2009


One-E-Way, Inc. v. International Trade Commission
  • Sughrue Mion PLLC
  • USA
  • June 12 2017

In One-E-Way v. ITC, the Federal Circuit reversed the ITC's determination that the claim language "virtually free from interference" is indefinite